Visilizumab

Visilizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD3 receptor
Clinical data
ATC code	none;
Identifiers
CAS Number	219716-33-3 ;
DrugBank	DB12053 ;
ChemSpider	none;
UNII	H18SKU3289;
KEGG	D06314;
ChEMBL	ChEMBL2108811;
	(verify)

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]

PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009.

Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]

References

"PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11.
"PDL Lands in a Hazard". 29 August 2007. Retrieved 2009-05-27.
Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov
Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/Metabolism Research and Reviews. 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985. S2CID 36595661.
Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov
Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, et al. (October 2009). "Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes" (PDF). Journal of Nuclear Medicine. 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100. S2CID 31980716.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11.

[2] "PDL Lands in a Hazard". 29 August 2007. Retrieved 2009-05-27.

[3] Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov

[4] Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/Metabolism Research and Reviews. 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985. S2CID 36595661.

[5] Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov

[6] Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, et al. (October 2009). "Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes" (PDF). Journal of Nuclear Medicine. 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100. S2CID 31980716.